Bulk tumor tissue

Bulk tumor tissue refers to the macroscopic, heterogeneous mass of a neoplasm, which includes not only malignant cells but also the tumor microenvironment (TME) consisting of stromal fibroblasts, immune cells, blood vessels, and the extracellular matrix (Source: NIH National Cancer Institute). It is not a specific molecular target, such as a receptor or enzyme, but rather a complex biological entity and a common sample type used in oncology for genomic and proteomic profiling (Source: Nature Reviews Cancer). While clinical interventions like surgery and radiation therapy aim to physically debulk the tumor tissue, pharmacological agents are designed to interact with specific molecular components within this mass (Source: StatPearls). A major challenge in the study and treatment of bulk tumor tissue is intra-tumor heterogeneity, where different spatial regions of the same tumor exhibit distinct genetic and phenotypic characteristics, often leading to incomplete treatment responses (Source: PubMed, PMID: 22405088). Furthermore, bulk molecular analysis (e.g., bulk RNA sequencing) provides an averaged signal that may obscure the presence of rare but clinically significant cell populations, such as cancer stem cells or therapy-resistant clones (Source: Cell, DOI: 10.1016/j.cell.2019.05.031).

Other names

Tumor massWhole tumor tissueNeoplastic tissueTumor specimen

Not applicable as a single molecular target; drugs typically target specific molecular pathways, receptors, or cell types within the bulk tumor mass.